About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Colorectal Cancer Clinical Trials in Maryland | 369 Studies | Clareo Health

Clinical Trials Colorectal CancerMaryland

Colorectal Cancer Clinical Trials in Maryland

Find 369 clinical trials for colorectal cancer near Maryland. Connect with research centers in your area.

All Colorectal Cancer trials nationwide All trials in Maryland

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 161-180 of 369 trials

TERMINATEDPhase 1/217 miles

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

NCT04408599

This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.

Advanced or Metastatic Solid TumorsOvarian CancerGastric Cancer+1 more

NextCure, Inc.46 participantsStarted Jun 2020

Bethesda, Maryland, United States • Hackensack, New Jersey, United States • New York, New York, United States +2 more locations

Active Not RecruitingPhase 1/217 miles

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NCT04913337

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

MesotheliomaGlioblastomaRenal Cell Carcinoma+12 more

NGM Biopharmaceuticals, Inc179 participantsStarted Jun 2021

Los Angeles, California, United States • Newport Beach, California, United States • Santa Monica, California, United States +24 more locations

Colorectal Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

Approved For Marketing17 miles

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

NCT02286492

The objective of the program is to provide access to TAS-102 to patients with metastatic colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy with TAS-102 and in whom therapy with TAS-102 is clinically indicated.

Colorectal Cancer Metastatic

Taiho Oncology, Inc.

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Fresno, California, United States +30 more locations

Active Not RecruitingPhase 217 miles

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

NCT03992456

This phase II trial studies how well retreatment with panitumumab works compared to standard of care regorafenib or trifluridine and tipiracil hydrochloride (TAS-102) in treating patients with colorectal cancer that is negative for RAS wild-type colorectal cancer has spread to other places in the body (metastatic), and/or cannot be removed by surgery (unresectable), and is negative for resistance mutations in blood. Treatment with panitumumab may interfere with the ability of tumor cells to grow and spread. Some tumors need growth factors to keep growing. Growth factor antagonists, such as regorafenib, may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving panitumumab may work better in treating patients with colorectal cancer than with the usual treatment of regorafenib or TAS-102.

Metastatic Colon AdenocarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal Adenocarcinoma+27 more

Academic and Community Cancer Research United12 participantsStarted Apr 2020

Scottsdale, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +15 more locations

TERMINATEDPhase 119 miles

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

NCT05824559

This is a Phase 1b open-label, multiple dose/schedule sequential study to determine the safety and efficacy of the oxidative phosphorylation (OxPhos) pathway inhibitor ME-344 in combination with bevacizumab in subjects with recurrent mCRC.

Colorectal Cancer

MEI Pharma, Inc.23 participantsStarted Aug 2023

Los Angeles, California, United States • Miami Beach, Florida, United States • Baltimore, Maryland, United States +4 more locations

COMPLETEDPhase 219 miles

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

NCT03473925

The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive refractory non-small cell lung cancer (NSCLC), castration resistant prostate cancer (CRPC) or microsatellite stable (MSS) colorectal cancer (CRC).

Solid TumorsNon-small Cell Lung CancerCastration Resistant Prostate Cancer+1 more

Merck Sharp & Dohme LLC107 participantsStarted Apr 2018

Scottsdale, Arizona, United States • Sarasota, Florida, United States • Baltimore, Maryland, United States +11 more locations

TERMINATEDPhase 131 miles

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

NCT05084859

This study is an open-label, multi-center, dose-escalation, dose expansion study in adult subjects with advanced solid tumors. The study will evaluate the safety, tolerability, PK, and preliminary anti-tumor efficacy of SM08502 administered orally (PO), once daily (QD), following a 5 days on 2 days off treatment schedule in combination with chemotherapy or hormonal therapy. Alternative dosing schedules may be explored in Part 1 if necessary. The recommended Part 2 dose and schedule for each combination will then be further evaluated in the Part 2 expansion. Dosing will occur in 21- or 28-day cycles (depending on the combination partner) and treatment with SM08502 will continue within each subject unless treatment is discontinued due to toxicity, disease progression, initiation of a new anti-neoplastic therapy, withdrawal of consent, the Sponsor terminates the study, or the subject no longer meets retreatment criteria.

Castration-resistant Prostate CancerNon-small Cell Lung CancerColorectal Cancer

Biosplice Therapeutics, Inc.30 participantsStarted Nov 2021

Tucson, Arizona, United States • Aurora, Colorado, United States • Aurora, Colorado, United States +17 more locations

COMPLETEDPhase 131 miles

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

NCT03819387

This is an open-label, non-controlled study conducted in two parts - Part A (dose escalation) followed by Part B (dose expansion).

Non-Small Cell Lung CancerPancreatic CancerColorectal Cancer

Nitto BioPharma, Inc.49 participantsStarted Mar 2019

Beverly Hills, California, United States • La Jolla, California, United States • Tampa, Florida, United States +6 more locations

TERMINATEDPhase 258 miles

Efficacy of Ginseng for Patients on Regorafenib

NCT02581059

This is a randomized, multi-center phase II study of ginseng in colorectal cancer patients treated with regorafenib to determine if ginseng will reduce fatigue in this patient population and improve adherence to regorafenib. Ninety (90) subjects will be enrolled and randomized using a 2:1 allocation, with 60 subjects enrolled in the regorafenib + ginseng group and 30 enrolled in the regorafenib + no ginseng group.

Colorectal CancerPalliative MedicineSupportive Care

Wake Forest University Health Sciences10 participantsStarted Apr 2016

Indianapolis, Indiana, United States • Indianapolis, Indiana, United States • Morristown, New Jersey, United States +2 more locations

Active Not RecruitingPhase 1110 miles

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

NCT04432857

This is an open-label, multicenter, phase Ib study to evaluate the safety and preliminary efficacy of AN0025 in combination with pembrolizumab in patients with locally advanced/metastatic tumors. It will include a dose-limiting toxicity observation phase followed by an expansion phase. All enrolled patients will be treated with AN0025 and Pembrolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent, or for a maximum of 35 cycles (approximately 2 years). The dose of pembrolizumab will remain constant at 200 mg every 3 weeks (Q3W) for each dose level of AN0025 and in each cohort.

Triple-negative Breast CancerNSCLC, Squamous or Non-SquamousUrothelial Carcinoma of the Bladder+2 more

Adlai Nortye Biopharma Co., Ltd.63 participantsStarted Aug 2020

St Louis, Missouri, United States • Houston, Texas, United States • Salt Lake City, Utah, United States +3 more locations

COMPLETEDPhase 1/2165 miles

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

NCT03761914

To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.

Acute Myelogenous LeukemiaOvarian CancerColorectal Cancer+2 more

Sellas Life Sciences Group26 participantsStarted Sep 2019

Santa Rosa, California, United States • Whittier, California, United States • Miami, Florida, United States +9 more locations

RECRUITINGPhase 1/2187 miles

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

NCT05824975

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more

GI Innovation, Inc.358 participantsStarted May 2023

Scottsdale, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States +8 more locations

COMPLETEDPhase 1187 miles

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

NCT04672460

This will be a Phase 1, open label, 2-sequence, crossover study to establish the BE of the current commercial formulation (Generation 3.1 talazoparib capsules) to the proposed talazoparib liquid-filled soft gelatin capsule (soft gel capsule) formulation after multiple dosing under fasting conditions in participants with advanced solid tumors. In addition, the effect of food on the PK of the proposed talazoparib soft gel capsule formulation will be evaluated in fixed sequence after the 2 BE assessment periods.

Advanced Solid TumorsSolid TumorsOvarian Cancer+5 more

Pfizer73 participantsStarted Dec 2020

Encinitas, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +28 more locations

COMPLETEDPhase 2241 miles

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

NCT02873195

This randomized phase II trial studies how well capecitabine and bevacizumab with or without atezolizumab work in treating patients with colorectal cancer that is not responding to treatment and has spread to other places. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab with capecitabine and bevacizumab may be a better way in treating colorectal cancer.

Metastatic Colorectal CarcinomaRecurrent Colorectal CarcinomaRefractory Colorectal Carcinoma+3 more

Academic and Community Cancer Research United133 participantsStarted Jul 2017

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Duarte, California, United States +7 more locations

COMPLETEDPhase 2250 miles

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

NCT03981614

This phase II trial studies how well binimetinib and palbociclib work compared to TAS-102 in treating patients with KRAS and NRAS mutation positive colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Binimetinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving binimetinib and palbociclib may work better compared to TAS-102 alone in treating patients with colorectal cancer.

Metastatic Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8+3 more

Academic and Community Cancer Research United102 participantsStarted Oct 2019

Scottsdale, Arizona, United States • Atlanta, Georgia, United States • Wichita, Kansas, United States +4 more locations

TERMINATEDPhase 1257 miles

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

NCT03621982

This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.

Head and Neck Cancer Squamous Cell CarcinomaNon-small Cell Lung CancerGastric Cancer+9 more

ADC Therapeutics S.A.78 participantsStarted Nov 2018

Palo Alto, California, United States • New Haven, Connecticut, United States • Portland, Oregon, United States +6 more locations

TERMINATEDPhase 3308 miles

Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer

NCT05223673

This is a randomized phase III study with a safety lead-in part in patients with KRAS/ NRAS and BRAF Wild Type metastatic colorectal cancer who have previously received treatment with oxaliplatin, irinotecan, fluoropyrimidines, anti-VEGF agents and anti-EGFR antibodies. The main objective of the safety lead-in part is to assess safety and tolerability of futuximab/modotuximab in combination with trifluridine/tipiracil. The primary objective of the phase III part is to compare Overall Survival of futuximab/modotuximab in combination with trifluridine/tipiracil vs trifluridine/tipiracil monotherapy in patients with tumours that are KRAS/NRAS and BRAF wild-type (WT).

Metastatic Colorectal Cancer

Institut de Recherches Internationales Servier7 participantsStarted Apr 2022

Ann Arbor, Michigan, United States • Cleveland, Ohio, United States • Edegem, Belgium +12 more locations

COMPLETEDPhase 3356 miles

COLOR II: Laparoscopic Versus Open Rectal Cancer Removal

NCT00297791

COLOR II is a randomized, international, multi center study comparing the outcomes of laparoscopic and conventional resection of rectal carcinoma below 15 cm with curative intent. Clinical and operative data will be collected centrally in the coordinating centre in Halifax, Canada. Quality of life and costs will be assessed on a national basis.

Nova Scotia Health Authority1,044 participantsStarted Jun 2004

Leuven, Belgium • Edmonton, Alberta, Canada • Halifax, Nova Scotia, Canada +32 more locations

COMPLETEDPhase 1377 miles

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

NCT01436656

CLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of daily administered LGX818 (daily, twice daily and/or every-other-day), a RAF kinase inhibitor. Patients with locally advanced or metastatic melanoma harboring the BRAF V600 mutation (during dose escalation phase and expansion phase) and patients with metastatic colorectal cancer harboring the BRAF V600 mutation (during the expansion phase) will be enrolled. The study consists of a dose escalation part were cohorts of patients will receive escalating oral doses of LGX818, followed by a safety dose expansion part were patients will be treated with oral dose of LGX818 given at the MTD or RP2D.

Melanoma and Metastatic Colorectal Cancer

Pfizer107 participantsStarted Sep 2011

Tampa, Florida, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States +21 more locations

TERMINATEDPhase 1/2413 miles

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

NCT05500508

A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.

CancerSolid TumorSolid Carcinoma+17 more

Aminex Therapeutics, Inc.15 participantsStarted Nov 2022

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States +4 more locations

PreviousPage 9 of 19Next

Other Conditions in Maryland

Breast Cancer Lung Cancer Prostate Cancer Melanoma Leukemia Lymphoma